Clinical Trial

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 16 locations 2026-04-01
Trial Details
NCT Number NCT06272812
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Biofabri, SLU, Universidad de Zaragoza
Conditions Tuberculosis (TB)
Enrollment 5,500 participants
Start Date 2025-02-19
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-31